Medtronic Secures Permanent CPT Codes for Urinary Incontinence and Hypertension Devices

  • Medtronic received Category I CPT code approvals for Altaviva™ (urinary incontinence) and Symplicity Spyral™ (hypertension) systems, replacing existing Category III codes.
  • New codes take effect January 2028, signaling established clinical adoption and reimbursement pathway progress.
  • Altaviva™ gained FDA approval in September 2025; Symplicity Spyral™ secured Medicare coverage in October 2025.
  • Altaviva™ targets 16M U.S. adults with urge urinary incontinence; Symplicity Spyral™ leverages global clinical data from 5,000+ patients.

Medtronic's CPT wins validate its strategy to address high-prevalence conditions with minimally invasive solutions. The approvals come as renal denervation regains traction post-clinical trial validation and urinary incontinence devices expand beyond traditional stimulation therapies. With Medicare coverage already secured for Symplicity Spyral™, the remaining hurdle is commercial payer alignment—a dynamic Medtronic now aims to accelerate through Category I code leverage.

Reimbursement Momentum
Whether Category I codes accelerate commercial payer coverage decisions for both systems.
Clinical Adoption
The pace at which physician utilization scales post-code implementation in January 2028.
Competitive Positioning
How Medtronic defends market share against emerging renal denervation and neuromodulation alternatives.